Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Comparative genomics analysis of Clostridium difficile epidemic strain DH/NAP11/106.

Kociolek LK, Gerding DN, Hecht DW, Ozer EA.

Microbes Infect. 2018 Apr;20(4):245-253. doi: 10.1016/j.micinf.2018.01.004. Epub 2018 Jan 31.

2.

Whole-genome analysis reveals the evolution and transmission of an MDR DH/NAP11/106 Clostridium difficile clone in a paediatric hospital.

Kociolek LK, Ozer EA, Gerding DN, Hecht DW, Patel SJ, Hauser AR.

J Antimicrob Chemother. 2018 May 1;73(5):1222-1229. doi: 10.1093/jac/dkx523.

3.

Complete Genome Sequence of Clostridioides difficile Epidemic Strain DH/NAP11/106/ST-42, Isolated from Stool from a Pediatric Patient with Diarrhea.

Ozer EA, Hauser AR, Gerding DN, Espinosa RO, Hecht DW, Kociolek LK.

Genome Announc. 2017 Sep 21;5(38). pii: e00923-17. doi: 10.1128/genomeA.00923-17.

4.

Trends in antimicrobial resistance among Bacteroides species and Parabacteroides species in the United States from 2010-2012 with comparison to 2008-2009.

Snydman DR, Jacobus NV, McDermott LA, Goldstein EJ, Harrell L, Jenkins SG, Newton D, Patel R, Hecht DW.

Anaerobe. 2017 Feb;43:21-26. doi: 10.1016/j.anaerobe.2016.11.003. Epub 2016 Nov 17.

PMID:
27867083
5.

Changes in the antibiotic susceptibility of anaerobic bacteria from 2007-2009 to 2010-2012 based on the CLSI methodology.

Hastey CJ, Boyd H, Schuetz AN, Anderson K, Citron DM, Dzink-Fox J, Hackel M, Hecht DW, Jacobus NV, Jenkins SG, Karlsson M, Knapp CC, Koeth LM, Wexler H, Roe-Carpenter DE; From the Ad Hoc Working Group on Antimicrobial Susceptibility Testing of Anaerobic Bacteria of CLSI.

Anaerobe. 2016 Dec;42:27-30. doi: 10.1016/j.anaerobe.2016.07.003. Epub 2016 Jul 15.

6.

Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients.

Kociolek LK, Gerding DN, Osmolski JR, Patel SJ, Snydman DR, McDermott LA, Hecht DW.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4896-900. doi: 10.1128/AAC.00714-16. Print 2016 Aug.

7.

Emergence and evolution of an international cluster of MDR Bacteroides fragilis isolates.

Sóki J, Hedberg M, Patrick S, Bálint B, Herczeg R, Nagy I, Hecht DW, Nagy E, Urbán E.

J Antimicrob Chemother. 2016 Sep;71(9):2441-8. doi: 10.1093/jac/dkw175. Epub 2016 May 30.

PMID:
27246231
8.

Diversity of Clostridium perfringens isolates from various sources and prevalence of conjugative plasmids.

Park M, Deck J, Foley SL, Nayak R, Songer JG, Seibel JR, Khan SA, Rooney AP, Hecht DW, Rafii F.

Anaerobe. 2016 Apr;38:25-35. doi: 10.1016/j.anaerobe.2015.11.003. Epub 2015 Nov 30.

PMID:
26608548
9.

Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027.

Wieczorkiewicz JT, Lopansri BK, Cheknis A, Osmolski JR, Hecht DW, Gerding DN, Johnson S.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):418-23. doi: 10.1128/AAC.01820-15. Print 2016 Jan.

10.

Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.

Gerding DN, Hecht DW, Louie T, Nord CE, Talbot GH, Cornely OA, Buitrago M, Best E, Sambol S, Osmolski JR, Kracker H, Locher HH, Charef P, Wilcox M.

J Antimicrob Chemother. 2016 Jan;71(1):213-9. doi: 10.1093/jac/dkv300. Epub 2015 Oct 3.

11.

Kibdelomycin is a potent and selective agent against toxigenic Clostridium difficile.

Miesel L, Hecht DW, Osmolski JR, Gerding D, Flattery A, Li F, Lan J, Lipari P, Polishook JD, Liang L, Liu J, Olsen DB, Singh SB.

Antimicrob Agents Chemother. 2014;58(4):2387-92. doi: 10.1128/AAC.00021-14. Epub 2014 Feb 10.

12.

Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009.

Snydman DR, Jacobus NV, McDermott LA, Golan Y, Goldstein EJ, Harrell L, Jenkins S, Newton D, Pierson C, Rosenblatt J, Venezia R, Gorbach SL, Queenan AM, Hecht DW.

Anaerobe. 2011 Aug;17(4):147-51. doi: 10.1016/j.anaerobe.2011.05.014. Epub 2011 Jun 2.

PMID:
21664469
13.

Phenotypic and genotypic characterization of tetracycline and minocycline resistance in Clostridium perfringens.

Park M, Rooney AP, Hecht DW, Li J, McClane BA, Nayak R, Paine DD, Rafii F.

Arch Microbiol. 2010 Oct;192(10):803-10. doi: 10.1007/s00203-010-0605-5. Epub 2010 Jul 27.

PMID:
20661548
14.

The novel antibacterial drug XF-70 is a potent inhibitor of Staphylococcus aureus infection of the burn wound.

Hurtuk MG, He LK, Szilagyi A, Gamelli RL, Hecht DW, Kennedy RH, Rhys-Williams W, Love WG, Shankar R.

J Burn Care Res. 2010 May-Jun;31(3):462-9. doi: 10.1097/BCR.0b013e3181db5265.

PMID:
20453736
15.

Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).

Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJ, Harrell L, Jenkins S, Newton D, Pierson C, Rihs JD, Yu VL, Venezia R, Finegold SM, Rosenblatt JE, Gorbach SL.

Clin Infect Dis. 2010 Jan 1;50 Suppl 1:S26-33. doi: 10.1086/647940.

PMID:
20067390
16.

Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment.

Johnson S, Schriever C, Patel U, Patel T, Hecht DW, Gerding DN.

Anaerobe. 2009 Dec;15(6):290-1. doi: 10.1016/j.anaerobe.2009.08.004. Epub 2009 Aug 18.

PMID:
19698797
17.

Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.

O'Connor JR, Galang MA, Sambol SP, Hecht DW, Vedantam G, Gerding DN, Johnson S.

Antimicrob Agents Chemother. 2008 Aug;52(8):2813-7. doi: 10.1128/AAC.00342-08. Epub 2008 Jun 16.

18.
19.

Characterization of BctA, a mating apparatus protein required for transfer of the Bacteroides fragilis conjugal element BTF-37.

Hecht DW, Kos IM, Knopf SE, Vedantam G.

Res Microbiol. 2007 Sep;158(7):600-7. Epub 2007 Jul 13.

PMID:
17720457
20.

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.

Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN.

Antimicrob Agents Chemother. 2007 Aug;51(8):2716-9. Epub 2007 May 21.

21.

Routine anaerobic blood cultures: back where we started?

Hecht DW.

Clin Infect Dis. 2007 Apr 1;44(7):901-3. Epub 2007 Feb 14. No abstract available.

PMID:
17342638
22.

National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.

Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, Finegold SM, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Yu V, Rihs J, Gorbach SL.

Antimicrob Agents Chemother. 2007 May;51(5):1649-55. Epub 2007 Feb 5.

23.

Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.

Sprandel KA, Drusano GL, Hecht DW, Rotschafer JC, Danziger LH, Rodvold KA.

Diagn Microbiol Infect Dis. 2006 Aug;55(4):303-9.

PMID:
16887471
24.

Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing.

Hecht DW.

Anaerobe. 2006 Jun;12(3):115-21. Epub 2005 Dec 6. Review. No abstract available.

PMID:
16765857
25.

Characterization of the Bacteroides fragilis pathogenicity island in human blood culture isolates.

Claros MC, Claros ZC, Hecht DW, Citron DM, Goldstein EJ, Silva J Jr, Tang-Feldman Y, Rodloff AC.

Anaerobe. 2006 Feb;12(1):17-22. Epub 2005 Aug 15.

PMID:
16701608
26.
28.

Clostridium clostridioforme: a mixture of three clinically important species.

Finegold SM, Song Y, Liu C, Hecht DW, Summanen P, Könönen E, Allen SD.

Eur J Clin Microbiol Infect Dis. 2005 May;24(5):319-24.

PMID:
15891914
29.

Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments.

Hecht DW.

Clin Infect Dis. 2004 Jul 1;39(1):92-7. Epub 2004 Jun 3.

PMID:
15206059
30.

Molecular characterization of imipenem-resistant, cfiA-positive Bacteroides fragilis isolates from the USA, Hungary and Kuwait.

Sóki J, Fodor E, Hecht DW, Edwards R, Rotimi VO, Kerekes I, Urbán E, Nagy E.

J Med Microbiol. 2004 May;53(Pt 5):413-9.

PMID:
15096551
31.

Antibiotics and anaerobes of gut origin.

Vedantam G, Hecht DW.

Curr Opin Microbiol. 2003 Oct;6(5):457-61. Review.

PMID:
14572537
32.

Emergence of fluoroquinolone resistance among Bacteroides species.

Golan Y, McDermott LA, Jacobus NV, Goldstein EJ, Finegold S, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Rihs J, Iannini P, Gorbach SL, Snydman DR.

J Antimicrob Chemother. 2003 Aug;52(2):208-13. Epub 2003 Jul 15.

PMID:
12865399
33.

Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.

Hecht DW, Osmolski JR.

Antimicrob Agents Chemother. 2003 Mar;47(3):910-6.

34.

In vitro activities of newer quinolones against bacteroides group organisms.

Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Goldstein E, Finegold S, Harrell L, Hecht DW, Jenkins S, Pierson C, Venezia R, Rihs J, Gorbach SL.

Antimicrob Agents Chemother. 2002 Oct;46(10):3276-9. Erratum in: Antimicrob Agents Chemother. 2003 Feb;47(2):831.

35.

National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000.

Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Goldstein EJ, Finegold SM, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Rihs J, Gorbach SL.

Clin Infect Dis. 2002 Sep 1;35(Suppl 1):S126-34.

PMID:
12173121
36.

Multilaboratory comparison of anaerobe susceptibility results using 3 different agar media.

Roe DE, Finegold SM, Citron DM, Goldstein EJ, Wexler HM, Rosenblatt JE, Cox ME, Jenkins SG, Hecht DW.

Clin Infect Dis. 2002 Sep 1;35(Suppl 1):S40-6.

PMID:
12173107
37.

Multilaboratory comparison of growth characteristics for anaerobes, using 5 different agar media.

Roe DE, Finegold SM, Citron DM, Goldstein EJ, Wexler HM, Rosenblatt JE, Cox ME, Jenkins SG, Hecht DW.

Clin Infect Dis. 2002 Sep 1;35(Suppl 1):S36-9.

PMID:
12173106
38.

Evolution of anaerobe susceptibility testing in the United States.

Hecht DW.

Clin Infect Dis. 2002 Sep 1;35(Suppl 1):S28-35.

PMID:
12173105
41.

Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.

Snydman DR, Jacobus NV, McDermott LA, Supran S, Cuchural GJ Jr, Finegold S, Harrell L, Hecht DW, Iannini P, Jenkins S, Pierson C, Rihs J, Gorbach SL.

Antimicrob Agents Chemother. 1999 Oct;43(10):2417-22.

43.

The Bacteroides fragilis BtgA mobilization protein binds to the oriT region of pBFTM10.

Sitailo LA, Zagariya AM, Arnold PJ, Vedantam G, Hecht DW.

J Bacteriol. 1998 Sep;180(18):4922-8.

44.

Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.

Snydman DR, McDermott L, Cuchural GJ Jr, Hecht DW, Iannini PB, Harrell LJ, Jenkins SG, O'Keefe JP, Pierson CL, Rihs JD, Yu VL, Finegold SM, Gorbach SL.

Clin Infect Dis. 1996 Dec;23 Suppl 1:S54-65.

PMID:
8953108
45.
46.

In vitro susceptibility of anaerobes to quinolones in the United States.

Hecht DW, Wexler HM.

Clin Infect Dis. 1996 Dec;23 Suppl 1:S2-8.

PMID:
8953099
47.
49.
50.

Plasmid labeling confirms bacterial translocation in pancreatitis.

Kazantsev GB, Hecht DW, Rao R, Fedorak IJ, Gattuso P, Thompson K, Djuricin G, Prinz RA.

Am J Surg. 1994 Jan;167(1):201-6; discussion 206-7.

PMID:
8311134

Supplemental Content

Loading ...
Support Center